GlassScriptPhysician profile
Randolph A Pinto
NPI 1285619411
$10,867.85
in general payments reported to CMS, 2019-2025
63 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $954 · 2021: $949 · 2022: $1,140 · 2023: $2,089 · 2024: $2,319 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,575.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.29 | 2019-2025 | |
| Amgen INC. | $1,027.34 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $849.50 | 2019-2025 | Airsupra, Nexium, Breztri |
| Lilly USA, LLC | $724.19 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $581.27 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Antares Pharma, INC. | $528.33 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $481.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $452.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $395.70 | 2019-2025 | Xarelto, Spravato |
| Esperion Therapeutics, INC. | $366.26 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $364.57 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.71 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $245.08 | 2019-2022 | |
| Exact Sciences Corporation | $244.76 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $239.03 | 2019-2025 | Rexulti |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.